PTC Therapeutics Inc. (PTCT) and MacroGenics Inc. (NASDAQ:MGNX) Comparing side by side – MS Wkly

This is a contrast between PTC Therapeutics Inc. (NASDAQ:PTCT) and MacroGenics Inc. (NASDAQ:MGNX) based on their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations. The two companies are Biotechnology and they also compete with each other.

Valuation & Earnings

Demonstrates PTC Therapeutics Inc. and MacroGenics Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 shows the return on assets, net margins and return on equity of the two firms.

Volatility & Risk

PTC Therapeutics Inc.s 1.74 beta indicates that its volatility is 74.00% more volatile than that of Standard & Poors 500. MacroGenics Inc. has a 2.3 beta and it is 130.00% more volatile than Standard & Poors 500.

Liquidity

PTC Therapeutics Inc.s Current Ratio is 3.3 while its Quick Ratio is 3.2. On the competitive side is, MacroGenics Inc. which has a 6.5 Current Ratio and a 6.5 Quick Ratio. MacroGenics Inc. is better positioned to pay off short and long-term obligations compared to PTC Therapeutics Inc.

Analyst Recommendations

PTC Therapeutics Inc. and MacroGenics Inc. Recommendations and Ratings are available in the next table.

PTC Therapeutics Inc. has a 21.85% upside potential and a consensus price target of $43. Competitively the consensus price target of MacroGenics Inc. is $27, which is potential 137.26% upside. Based on the results shown earlier, MacroGenics Inc. is looking more favorable than PTC Therapeutics Inc., analysts view.

Institutional and Insider Ownership

PTC Therapeutics Inc. and MacroGenics Inc. has shares owned by institutional investors as follows: 85.61% and 95.8%. About 0.3% of PTC Therapeutics Inc.s share are owned by insiders. Comparatively, 0.1% are MacroGenics Inc.s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year PTC Therapeutics Inc. has stronger performance than MacroGenics Inc.

Summary

On 7 of the 12 factors PTC Therapeutics Inc. beats MacroGenics Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The companys lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy. In addition, the companys product candidate in cancer stem cell program include PTC596, an orally bioavailable and potent small molecule, which has completed phase I clinical trials that targets tumor stem cell populations by reducing the activity and amount of a protein called BMI1. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The companys advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate. In addition, the companys products include MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; and MGD014, a DART molecule that targets human immunodeficiency virus, or HIV-infected cells, and CD3-expressing T cells. It has collaboration and license agreements with Janssen Biotech, Inc.; Les Laboratoires Servier and Institut de Recherches Servier; Boehringer Ingelheim GmbH; Pfizer, Inc.; and Green Cross Corp. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read this article:
PTC Therapeutics Inc. (PTCT) and MacroGenics Inc. (NASDAQ:MGNX) Comparing side by side - MS Wkly